Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF New

Name: Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF
Brand: R&D Systems
SKU: 11359-CV
Price: 548 USD

R&D Systems, Inc. a Bio-Techne Brand

Catalog # 11359-CV

Product Datasheet / COA / SDS

His-tag (GCN4-IZ)

Catalog #

Availability

Size / Price

Qty

Setting the standard in quality research reagents

Key Product Details

Source:	HEK293
Accession #:	YP_009724390.1
Applications:	Bioactivity

View Full Technical Details for Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF

Product Specifications for Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF

Source

Human embryonic kidney cell, HEK293-derived sars-cov-2 Spike protein

SARS-COV-2 BQ.1.1 Spike (Val16â€“Lys1211) (Thr19Ile, Leu24del, Pro25del, Pro26del, Ala27Ser, His69del, Val70del, Gly142Asp, Val213Gly, Gly339Asp, Arg346Thr, Ser371Phe, Ser373Pro, Ser375Phe, Thr376Ala, Asp405Asn, Arg408Ser, Lys417Asn, Asn440Lys, Lys444Thr, Leu452Arg, Asn460Lys, Ser477Asn, Thr478Lys, Glu484Ala, Phe486Val, Gln498Arg, Asn501Tyr, Tyr505His, Asp614Gly, His655Tyr, Asn679Lys, Pro681His, Asn764Lys, Asp796Tyr, Gln954His, Asn969Lys) (Arg682Ser, Arg685Ser, Lys986Pro, Val987Pro) Accession # YP_009724390.1	HP	2-GSL	GCN4-IZ	2-GSL	6-His tag
N-terminus					C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal sequence Analysis

Val16

Predicted Molecular Mass

138 kDa

SDS-PAGE

137-167 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 Fc Chimera (Catalog # 10544-ZN).

Scientific Data Examples for Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF

	Recombinant SARS-CoV-2 BQ.1.1 Spike (GCN4-IZ) His-tag Protein Binding Activity. Recombinant SARS-CoV-2 BQ.1.1 Spike (GCN4-IZ) His-tag Protein (Catalog # 11359-CV) binds Recombinant Human ACE-2 Fc Chimera (10544-ZN) in a functional ELISA.
	Recombinant SARS-CoV-2 BQ.1.1 Spike (GCN4-IZ) His-tag Protein SDS-PAGE. 2 μg/lane of Recombinant SARS-CoV-2 BQ.1.1 Spike (GCN4-IZ) His-tag Protein (Catalog # 11359-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 137‑162 kDa.

Formulation, Preparation and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11359-CV

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: Spike

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS-CoV and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) (1). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds a metallopeptidase, Angiotensin-Converting Enzyme 2 (ACE-2), but with much higher affinity and faster binding kinetics through the receptor binding domain (RBD) located in the C-terminal region of S1 subunit (6). It has been demonstrated that the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (7, 8). Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE-2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (9). There is also promising work showing that the RBD may be used to detect presence of neutralizing antibodies present in a patient's bloodstream, consistent with developed immunity after exposure to the SARS-CoV-2 (10). Based on amino acid (aa) sequence homology, the S protein shares 75% and 29% identity with SARS-CoV-1 and MERS, respectively. Several emerging SARS-CoV-2 genomes have been identified including the Omicron, or B.1.1.529, variant. First identified in November 2021 in South Africa, the Omicron variant quickly became the predominant SARS-CoV-2 variant and is considered a variant of concern (VOC). The Omicron variant contains 32 mutations in the S protein, 3 to 4 times more than in other SARS-CoV-2 variants, that potentially affect viral fitness and transmissibility (11). Of these mutations,15 are located in the RBD domain and allow the Omicron variant to bind ACE-2 with greater affinity and, potentially, increased transmissibility (11, 12). Several additional mutations throughout the S protein have been shown or are predicted to enhance spike cleavage and could aid transmission (13-15). The study of the Omicron variant's impact on immune escape and reduced neutralization activity to monoclonal antibodies along with an increased risk of reinfection, even among vaccinated individuals, remains ongoing (16). The BQ.1.1 variant is derived from the BA.5 strain but showed poor response to BA.5-bivalent-booster (17).

Item	Value
References	Wu, F. et al. (2020) Nature 579:265. Tortorici, M.A. and D. Veesler (2019) Adv. Virus Res. 105:93. Bosch, B.J. et al. (2003) J. Virol. 77:8801. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871. Millet, J.K. and G.R. Whittaker (2015) Virus Res. 202:120. Ortega, J.T. et al. (2020) EXCLI J. 19:410. Wang, K. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1. Isabel, S. et al. (2020) Sci Rep. 10, 14031. https://doi.org/10.1038/s41598-020-70827-z. Tai, W. et al. (2020) Cell. Mol. Immunol. 17:613. Okba, N. M. A. et al. (2020). Emerg. Infect. Dis. https://doi.org/10.3201/eid2607.200841. Shah, M. and Woo, H.G. (2021) bioRxiv https://doi.org/10.1101/2021.12.04.471200. Lupala, C.S. et al. (2021) bioRxiv https://doi.org/10.1101/2021.12.10.472102. Zhang, L. et al. (2020) Nat Commun. 11:6013. Lasek-Nesselquist, E. et al. (2021) medRxiv https://doi.org/10.1101/2021.03.10.21253285. Scheepers, C. et al. (2021) medRxiv https://doi.org/10.1101/2021.08.20.21262342. Callaway, E. and Ledford, H. (2021) Nature 600:197. Kurhade,C.,et al.(2022) Nature Med. https://doi.org/10.1038/s41591-022-02162-x.
Long Name	Spike Protein
Entrez Gene IDs	918758 (HCoV-229E); 2943499 (HCoV-NL63); 39105218 (HCoV-OC43); 37616432 (MERS-CoV); 1489668 (SARS-CoV); 43740568 (SARS-CoV-2)
Alternate Names	2019-nCoV S Protein, 2019-nCoV Spike, COVID-19 Spike, E2, Human coronavirus spike glycoprotein, Peplomer protein, S Protein, S glycoprotein, SARS-COV-2 S protein, SARS-COV-2 Spike glycoprotein, SARS-CoV-2, SARSCOV2 Spike protein, Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein, Spike, Spike glycoprotein, surface glycoprotein

Citations for Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF

Please visit our Instrument Citation Database to search our collection of scientific articles that feature our instruments.

Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF New

R&D Systems, Inc. a Bio-Techne Brand

Key Product Details

Customers also Viewed

Product Specifications for Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF

Scientific Data Examples for Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF

Formulation, Preparation and Storage

Carrier Free

Reconstitution Calculator

Background: Spike

Citations for Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF

Product Documents for Recombinant SARS-CoV-2 BQ.1.1 Spike GCN4-IZ His Protein, CF

Product Datasheets

COA

Certificate of Analysis

SDS

Bio-Techne Brands

Stay Connected